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Abstract
Background and objectives: The combination of ketamine and remifentanil seems to be associated 
with better analgesia and duration. The aim of this study was to evaluate whether a ketamine-
remifentanil combination promotes improved postoperative analgesia.
Methods: Prospective, randomized, double blind study of 40 patients undergoing video laparoscopic 
cholecystectomy. Anesthesia was performed with remifentanil, propofol, atracurium, and 50% oxygen. 
Group 1 (GI) patients received remifentanil (0.4 mcg.kg-1.min-1) and ketamine (5 mcg.kg-1.min-1) and 
Group 2 (G2) received remifentanil (0.4 mcg.kg-1.min-1) and saline solution. Morphine 0.1 mg.kg-1 was 
administered at the end of the procedure, and postoperative pain was treated with morphine via 
PCA. We evaluated the severity of postoperative pain by a numerical scale from zero to 10 during 
24 hours. We registered the time to the ﬁ rst analgesic supplementation, amount of morphine used 
in the ﬁ rst 24 hours, and adverse effects.
Results: There was a decrease in pain severity between extubation and other times evaluated 
in G1 and G2. There was no signiﬁ cant difference in pain intensity between the groups. There 
was no difference between G1 (22 ± 24.9 min) and G2 (21.5 ± 28.1 min) regarding time to ﬁ rst 
dose of morphine and dose supplement of morphine consumed in G1 (29 ± 18.4 mg) and G2 
(25.1 ± 13.3 mg).
Conclusion: The combination of ketamine (5 mcg.kg-1.min-1) and remifentanil (0.4 mcg.kg-1.min-1) 
for cholecystectomy did not alter the severity of postoperative pain, time to ﬁ rst analgesic 
supplementation or dose of morphine in 24 hours.
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. 
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Introduction
Although there have been many advances in the pathophysiol-
ogy of postoperative pain and emergence of new drugs and 
analgesic techniques, postoperative pain control remains 
inadequate 1,2. About half of patients undergoing surgeries 
presents with severe pain during hospitalization 3.
Remifentanil is an opioid with very short action 4. It is 
used for analgesia when fast recovery is important 5. Due to 
the nonspeciﬁ c metabolism by plasma and tissue esterases, 
its clearance is independent from the liver function 4. In 
subjects with renal impairment, there was no increased 
sensitivity to remifentanil 5. Despite these advantages, 
there is also a rapid termination of the analgesic effect. 
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Moreover, some authors have reported that a factor in-
volved in the hyperalgesia is the short duration of action 
of opioids, such as remifentanil 7-10. The main mechanism 
of hyperalgesia induced by opioids is the activation of 
N-methyl-D-aspartate (NMDA) receptors 11-14.
Ketamine is a NMDA receptor antagonist, which acts by 
non-competitive blockage, binding itself to the intra-channel 
phencyclidinic site and changing the channel opening time. 
S(+) Ketamine afﬁ nity for this binding site is three to four 
times higher compared to isomer R(-). Analgesic potency of 
S(+) ketamine is two times that of racemic mixture 15.
We observed preemptive analgesic effect of S(+)ketamine 
and reduction of the hyperalgesia phenomenon induced by 
remifentanil, using low-dose infusion intravenously 7,16,17. 
When administered both prior to anesthesia induction and 
throughout the perioperative period, ketamine is able to 
promote signiﬁ cant reduction in the consumption of anes-
thetic agents during surgical anesthetic procedure, exerting 
an “opioid sparing” effect, aside from promoting adequate 
postoperative analgesia 18.
Thus, the combination of ketamine and remifentanil 
seems to relate to better analgesia and duration. The aim 
of this study was to evaluate whether the combination of 
ketamine and remifentanil promotes improved postopera-
tive analgesia.
Method
After approval by the Ethics Committee and signing of in-
formed consent, we conducted a prospective, randomized, 
double-blind study of 40 patients over 18 years of age, both 
sexes, ASA I or II, undergoing video laparoscopic cholecystec-
tomy. Patients were allocated into two equal groups. Group 
allocation was determined by drawing envelopes containing 
numbers. On the morning of the operation and before starting 
anesthesia, a nurse or anesthesiologist blind to the patient’s 
group opened this patient’s envelope and prepared the sy-
ringes with remifentanil and ketamine or remifentanil and 
saline. None of the other researchers involved in the study 
or collecting data knew which group the patient belonged. 
In case of an emergency, the anesthesiologist attending the 
patient could see the group to which he belongs, breaking the 
protocol. Patients with chronic pain, myocardial ischemia, 
psychiatric illness, drug user, and those receiving opioids in 
the previous week were excluded.
Monitoring was performed with cardioscope, capnog-
raphy, pulse oximetry, noninvasive blood pressure, and 
thermometer. Infusion was administered with midazolam 
(3 mg, 30 min), remifentanil (1 mcg.kg-1), propofol (2-4 mg.kg-1), 
and atracurium (0.5 mg.kg-1). G1 received remifentanil 
(0.4 mcg.kg-1.min-1) and ketamine (5 mcg.kg-1.min-1) and G2 
received remifentanil (0.4 mcg.kg-1.min-1) and saline (0.9%). 
Remifentanil was increased or decreased as needed, based 
on hemodynamic data (hypotension, defined as systolic 
blood pressure below 80 mm Hg or mean arterial blood 
pressure below 60 mm Hg). Infusion of solutions was main-
tained until wound closure. Atracurium doses were titrated 
to maintain muscle relaxation. Anesthesia was maintained 
with sevoﬂ urane and 50% oxygen without nitrous oxide. 
Before extubation, atropine (0.02 mg.kg-1), neostigmine 
(0.04 mg.kg-1), metoclopramide (20 mg), and ondansetron 
(4 mg) were administered. Morphine (0.1 mg.kg-1) was ad-
ministered at the end of surgery. 
Postoperative pain was treated with morphine via patient 
controlled analgesia (PCA) by intravenous route, with bolus 
of 2 mg in 3 mL, 10 minutes safety interval (administration 
blockade), dose limit of 20 mg in four hours, and without 
infusion. 
We registered the total dose of remifentanil used during 
operation. To evaluate the severity of postoperative pain, a 
numerical scale from zero to 10 was used (where zero: no 
pain and 10: the most severe pain possible; scores between 
one and four: mild pain; ﬁ ve and six: moderate pain; and 
seven to 10: severe pain). Evaluations were made every 30 
minutes during four hours and six, 12, 18 and 24 hours after 
awakening. Time to ﬁ rst postoperative analgesic supple-
mentation, amount of analgesic used during 24 hours, and 
adverse effects were registered.
The statistical program used to calculate the number of 
patients and analyze the results was the Instat Graph®. A 
difference of 3 cm in pain intensity was considered clinically 
signiﬁ cant. Based on preliminary assessment, we estimated 
a standard deviation (SD) score of pain intensity within 
group of 2.2 7. For a power of 80% and a conﬁ dence interval 
of 95%, the sample size for each group was calculated at 15 
patients. Data were expressed as mean ± standard deviation. 
We used the Mann Whitney test for remifentanil dosage, 
duration of anesthesia and surgical procedure, time to sup-
plementation need, total dose of morphine used, and pain 
intensity between groups; the Student’s t-test for weight, 
age, height, and body mass index; ANOVA for pain intensity 
during evolution; and Fisher’s exact test for gender, ASA, 
and adverse effects. We used central tendency, mean, and 
dispersion (standard deviation) measurements. We set the 
statistical signiﬁ cance level at 5%.
Results
Patient’s demographic data were similar (Table 1). Duration 
of operation was 131.2 ± 39.5 min in G1 and 128 ± 57.5 min 
in G2, with no statistically signiﬁ cant difference between 
groups (p = 0.279, Mann-Whitney). Duration of anesthesia was 
173.2 ± 39.9 min in G1 and 175.1 ± 63.8 min in G2, with 
no statistically significant difference between groups 
(p = 0.250, Mann-Whitney). Remifentanil dose used was 
0.35 ± 0.10 mcg.kg-1.min-1 in G1 and 0.38 ± 0.10 mcg.kg-1.
min-1 in G2, with no statistically signiﬁ cant difference be-
tween groups (p = 0.310, Mann-Whitney).
There was a signiﬁ cant decrease in pain intensity by the 
verbal numerical scale between the time after awakening 
and other times evaluated in G1. There was no statistically 
signiﬁ cant difference in pain intensity between groups at 
each time evaluated (Table 2).
There was no difference between G1 (22 ± 24.9 min) and 
G2 (21.5 ± 28.1 min) in time to ﬁ rst dose of postoperative 
morphine supplementation (p = 0.516, Mann-Whitney test). 
There was no signiﬁ cant difference between groups regarding 
additional dose of morphine consumed in G1 (29 ± 18.4 mg) 
and G2 (25.1 ± 13.3 mg) (p = 0.598, Mann-Whitney test).
Adverse effects were agitation (G1: 3 and G2: 1, p = 
0.605), hallucinations (G1: 3, p = 0.231), vertigo (G1: 6 and 
G2: 12; p = 0.111), discomfort (G1: 10 and G2: 5; p = 0.191), 
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diplopia (G1: 1, p = 1.00), nystagmus (G1: 2, p = 0.487), loss 
of reality perception (G1: 1, p = 1.00), change in hearing 
(G1: 1, p = 1.00), reduced visual acuity (G1: 1, p = 1.00), 
malaise (G1: 11 and G2: 7, p = 0.341), nausea (G1 18 and 
G2: 15, p = 0.407), vomiting (G1: 12 and G2: 4; p = 0.022), 
and pruritus (G1: 2 and G2: 1; p = 1.00).
Discussion
Cholecystectomy was chosen because it is a procedure that 
provokes nociceptive stimulus sufﬁ cient to cause algogenic 
substance release, which allows evaluation of the analgesic 
effect of drugs. The study was conducted only with patients 
undergoing laparoscopic procedure because the stimulus in-
tensity was similar. Patients’ age group was 40-50 years, and 
females were most affected, as in most studies of patients 
undergoing cholecystectomy 19,20. The frequency of gallstones 
increases with age, more signiﬁ cantly after the age of 40 21. 
Females are more predisposed to stone formation due to 
hormonal factors 21,22. Patients of this study were overweight, 
which is a risk factor for gallstone 21,23.
Dosage of remifentanil used was based on the ideal weight 
of patients, as recommended by a study in the literature 24. 
This is due to the fact that remifentanil volume of distribution 
is small, limited primarily to central compartment. In one 
study, the authors recommend using remifentanil bolus of 
1 mcg.kg-1, followed by an infusion of 0.5 mcg.kg-1.min-1, 
titrated according to surgical stimulation 25.
The factors that seem to be more associated with severe 
postoperative pain after the use of remifentanil are age (over 
16 years), duration of surgery (> 2 hours), and high dosage 
use 26,27. In this study, the duration of surgery was greater 
than two hours in both groups and remifentanil dosage was 
high and similar between groups (> 0.3 mcg.kg-1.min-1), which 
may be associated with more intense postoperative pain.
There is a study that assesses the analgesic effect of 
ketamine-remifentanil combination 18. Several studies of 
other surgical procedures were conducted using ketamine 
and remifentanil 7,28-30. Due to the effects on NMDA recep-
tors, ketamine can reduce central sensitization and intensity 
of postoperative pain. The combination of ketamine and 
remifentanil may promote prolonged analgesia, since this 
opioid’s great disadvantage of producing no analgesic ef-
fect after infusion discontinuation. A study has shown that 
ketamine administration both before induction of anesthesia 
and during surgery markedly reduced the need for opioids, 
in addition to adequate postoperative analgesia18. 
Table 1  Demographic Data of Patients.
G1 (n = 20) G2 (n = 20) p
Age (years) 46.0 ± 12.5 45.5 ± 16.1 0.9221*
Weigh (Kg) 76.2 ± 15.3 75.5 ± 15.3 0.8943*
Height (cm) 165.7 ± 9.8 163.3 ± 11.6 0.3247*
BMI (kg.m-2) 26.9 ± 4.9 28.1 ± 6.2 0.5241*
Sex (M/F) 4 / 16 3 / 17 1.0000#
ASA (I/II) 8 / 12 11 / 9 0.5272#
G1: Ketamine + Remifentanil; G2: Remifentanil; BMI: body mass index; #: Fisher’s test; *: Student’s t-test.
Table 2  Pain Intensity upon Awakening.
Times (h) G1 (n= 20) G2 (n= 20) p1
1/2 6.1 ± 3.2 6.0 ± 2.3 0.6449
1 4.6 ± 2.8 4.4 ± 2.2 0.8602
1 ½ 3.3 ± 2.3 2.7 ± 2.1 0.4004
2 2.0 ± 2.2 1.4 ± 1.5 0.4878
2 ½ 1.3 ± 1.7 1.2 ± 1.7 0.7535
3 1.1 ± 1.5 1.1 ± 1.6 0.8161
3 ½ 1.1 ± 1.7 1.1 ± 1.4 0.7015
4 1.2 ± 1.9 1.0 ± 1.3 0.8261
6 0.9 ± 1.2 0.5 ± 0.9 0.2224
12 1.7 ± 1.9 1.1 ± 1.2 0.3682
18 1.8 ± 1.9 1.1 ± 1.3 0.3829
24 1.5 ± 1.3 0.5 ± 0.7 0.0510
p2 0.0001 0.0001
G1: Ketamine + Remifentanil; G2: Remifentanil; 1: Mann-Whitney test; 2: ANOVA.
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In some studies that did not assess the combination with 
remifentanil administered intravenously during the intra-
operative period, ketamine decreased pain intensity and 
opioid consumption postoperatively 31-34. From such evidence, 
protocols were developed to evaluate the combination of 
ketamine and remifentanil.
This study used 5 mcg.kg-1.min-1, without initial bolus 
dose. This dose, which is considered low, was also used in 
another study 10. A dose is considered low when < 1 mg.kg-1 
(intravenous bolus) or ≤ 20 mcg.kg-1.min-1 (infusion) 34. The 
doses used for induction were 0.15 mg.kg-1 30, 0.3 mg.kg 17, 
and 0.5 mg.kg-1 7,29. For infusion, the authors used 
0.3 mcg.kg-1.min-1 17, 2 mcg.kg-1.min-1 30, 4 mcg.kg-1.min-1 29, 
and 5 mcg.kg-1.min-1 7. Moreover, in one study, infusion was 
maintained with 2 mcg.kg-1.min-1 for the ﬁ rst 48 hours post-
operatively 7. Differences in infusion dosage and use of bolus 
for induction and postoperative maintenance may modify the 
results of the studies.
Adverse effects caused by remifentanil increased as the 
dose increased. In a multicenter study, during the period of 
induction or maintenance with remifentanil, adverse events 
occurred in about 2% of patients. The most common were 
hypotension, hypertension, and bradycardia 38. These ef-
fects were not observed in this study. In this study, the most 
prevalent adverse effects in both groups were nausea and 
vomiting, despite the use of metoclopramide and ondanset-
ron administered before extubation. Several factors may 
have contributed to this, such as the use of inhalational an-
esthetic, laparoscopic procedure, being overweight, female 
prevalence, and postoperative analgesia with morphine via 
PCA 39-41. Other effects (hallucinations, diplopia, nystagmus, 
loss of reality perception) are related to ketamine. Besides 
the lack of analgesic effect, there was an increase of adverse 
effects related to ketamine in G1.
One can conclude that the combination of ketamine 
(5 mcg.kg-1.min-1) and remifentanil (0.4 mcg.kg-1.min-1) 
for video laparoscopic cholecystectomy did not alter the 
intensity of postoperative pain, time to ﬁ rst analgesic sup-
plementation or morphine dose during 24 hours. 
The difference in results may be related to surgical 
stimulation intensity, amount of remifentanil used during 
operation, as well as the dose of ketamine used, in addition 
to the study method, which may modify the response of 
ketamine-remifentanil combination. 
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